SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:6c482f47-315b-4966-abbb-63959d831199"
 

Search: onr:"swepub:oai:lup.lub.lu.se:6c482f47-315b-4966-abbb-63959d831199" > Continued benefit d...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A : Interim analysis from the LEOPOLD Kids extension study

Kenet, Gili (author)
Sheba Medical Center
Ljung, Rolf (author)
Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pediatrisk hematologi,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Paediatric Haematology Research Unit,Lund University Research Groups,Skåne University Hospital
Rusen, Luminita (author)
Sanador hospital
show more...
Kerlin, Bryce A (author)
Ohio State University
Blanchette, Victor (author)
Hospital for Sick Children, Toronto
Saulytė Trakymienė, Sonata (author)
Vilnius University Hospital
Uscatescu, Valentina (author)
Fundeni Clinical Institute
Beckmann, Horst (author)
Bayer Pharma AG
Tseneklidou-Stoeter, Despina (author)
Bayer Pharma AG
Church, Nikki (author)
Bayer Corporation, USA
show less...
 (creator_code:org_t)
Elsevier BV, 2020
2020
English 6 s.
In: Thrombosis Research. - : Elsevier BV. - 1879-2472 .- 0049-3848. ; 189, s. 96-101
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • INTRODUCTION: BAY 81-8973 (Kovaltry®), a recombinant factor VIII (rFVIII) product, was efficacious and well tolerated in paediatric previously treated patients (PTPs) with severe haemophilia A for ≥50 exposure days (EDs) in the LEOPOLD Kids study. Because long-term prophylaxis (≥100 EDs) can provide substantial patient benefits, FVIII products should demonstrate long-term safety and efficacy.AIM: To demonstrate long-term (≥100 EDs) efficacy and safety of BAY 81-8973 in paediatric PTPs.METHODS: PTPs aged ≤12 years with severe haemophilia A without inhibitors could continue in the ongoing open-label extension study after completing ≥50 EDs in the LEOPOLD Kids main study. Patients received BAY 81-8973 for prophylaxis (25-50 IU/kg ≥2×/week), bleed treatment, and surgery. Bleeds were documented in electronic patient diaries. Inhibitor development was monitored every 6 months.RESULTS: At the August 2017 interim data cutoff, 46 patients (median [range] age at enrolment, 6.0 [1.0-11.0] years) had spent a median (range) of 602.5 (148-1069) EDs and 4.6 (1.0-5.9) years in the main plus extension studies. Median (quartile [Q]1; Q3) annualised bleeding rate for bleeds within 48 h after a prophylaxis infusion and total bleeds was 1.0 (0.2; 1.9) and 2.0 (0.4; 3.6), respectively. Most (>94%) bleeds were mild or moderate; 71.8% were treated with ≤1 infusion. BAY 81-8973 was also well tolerated with only one treatment-related adverse event (transient, low-titre inhibitor which did not require treatment adjustment).CONCLUSION: BAY 81-8973 was efficacious for prophylaxis and treatment of bleeds during >4.5 years in paediatric PTPs with severe haemophilia A.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view